263896-27-1

Basic information

• Product Name: 6-ETHYL-2,3-DIHYDROQUINOLIN-4(1H)-ONE
• Synonyms: 6-ETHYL-2,3-DIHYDROQUINOLIN-4(1H)-ONE;6-Ethyl-2,3-dihydro-1H-quinolin-4-one;6-ethyl-2,3-dihydro-4(1H)-Quinolinone
• CAS NO: 263896-27-1
• Molecular Formula: C₁₁H₁₃NO
• Molecular Weight: 175.22702
• Mol File: 263896-27-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-ETHYL-2,3-DIHYDROQUINOLIN-4(1H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-ETHYL-2,3-DIHYDROQUINOLIN-4(1H)-ONE(263896-27-1)
• EPA Substance Registry System: 6-ETHYL-2,3-DIHYDROQUINOLIN-4(1H)-ONE(263896-27-1)

Safety Data

• Hazardous Substances Data: 263896-27-1(Hazardous Substances Data)

Usage

General Description

6-Ethyl-2,3-dihydroquinolin-4(1h)-one is a chemical compound belonging to the class of organic compounds known as dihydroquinolones, characterized by a quinoline moiety bearing a ketone at the fourth carbon atom. Its molecular formula is C12H13NO and has a molar mass of 189.236 g/mol. It is also identified by its systematic name, Ethylquinolin-2(1H)-one. The properties of this compound, such as solubility and boiling point, are not extensively documented. Possible uses or applications of this chemical are undetermined due to limited available data.

Upstream product

• 676136-36-0 ethyl 3-(4-ethylphenylamino)propanoate 
• 263896-26-0 3-(4-ethylphenylamino)propionic acid 
• 589-16-2 4-aminoethylbenzene 

Downstream Products

• 676136-37-1 benzyl 6-ethyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate 

Relevant articles and documents

Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens

Potent nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase have been derived from a file compound high throughput screening hit. Optimized compounds show excellent antibacterial activity against staphylococcal and enterococcal pathogen

METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.